Biotechs Drive Oncology Growth with Precision Medicine Breakthroughs
The biotech sector has seen a significant surge in investment in oncology therapeutics, driven by the potential for precision medicine to revolutionize cancer treatment.
According to BioPharma Dive data, over $3.9 billion of the $9 billion invested in venture capital-funded biotechs in the first half of 2026 went towards companies developing cancer and immunology drugs, accounting for over 40% of total funds raised.
The global oncology drugs market is projected to grow from $256.5 billion in 2025 to almost $700 billion by 2034, representing an 11.8% compound annual growth rate (CAGR).
This growth presents an opportunity for investors to add biotech exchange-traded funds (ETFs) to their portfolios.
Several prominent biotechs are driving the cancer drug revolution, including Moderna, Amgen, Illumina, Iovance Biotherapeutics, and Halozyme Therapeutics. These companies have made significant breakthroughs in various types of cancers and have established themselves as key players in the sector.